Posted in | News | Laser | Imaging | Medical Optics

The Oyamo Group Places Order for the First CT Laser Mammography System for Israel

Imaging Diagnostic Systems, Inc., a pioneer in laser optical breast cancer imaging systems, announced today that its distributor The Oyamo group has place an order for the first CT Laser Mammography System (CTLM(R)) for Jerusalem, Israel.

The Oyamo group obtained the import license from the Israel Ministry of Health which permitted the shipment and initiated the purchase order. The CTLM system will be placed in the prestigious hospital Hadassah, located in the heart of Jerusalem. The Hadassah University Medical Center is a tertiary care referral facility, known for pioneering new medical techniques. A premier teaching hospital and research center, the Medical Center is equipped with the most sophisticated diagnostic, treatment and research equipment enabling its world renowned faculty to furnish the most modern medical care in an atmosphere that embraces excellence.

Dr. Miri Sklair, Head of Hadassah's Department of Mammography, will use the CTLM(R) system in addition to Mammography and Ultrasound in detecting breast cancer. Mr. Offer Hameiri, President of the Oyamo Group, quoted that he is "excited that a prestigious Medical Institution such as Hadassah, is going to be the pioneer for CTLM(R) in Israel."

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.